Case Report

An Unusual Case of Extranodal Diffuse Large B-Cell Lymphoma Infiltrating Skeletal Muscle: A Case Report and Review of the Literature

Joseph Hatem and Agata M. Bogusz

Department of Pathology and Laboratory Medicine, the University of Pennsylvania, Philadelphia, PA 19104, USA

Correspondence should be addressed to Agata M. Bogusz; agata.bogusz@uphs.upenn.edu

Received 18 February 2016; Accepted 18 April 2016

Academic Editor: Mirella Marino

Copyright © 2016 J. Hatem and A. M. Bogusz. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL), accounting for approximately 30–40% of cases [1, 2]. DLBCL is heterogeneous in its clinical presentation, response to treatment, and biology [3]. The current standard of care is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), which results in cure rates exceeding 50% [3]. An accurate diagnosis and the International Prognostic Index (IPI), a clinical tool developed by oncologists, which takes into account the patient’s age, stage of disease, lactate dehydrogenase (LDH) level, performance status, and number of extranodal sites (one or more than one), are together the most important factors in determining therapy modalities and predicting outcome of patients with aggressive NHL [3].

1. Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL), accounting for approximately 30–40% of cases [1, 2]. DLBCL is heterogeneous in its clinical presentation, response to treatment, and biology [3]. The current standard of care is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), which results in cure rates exceeding 50% [3]. An accurate diagnosis and the International Prognostic Index (IPI), a clinical tool developed by oncologists, which takes into account the patient’s age, stage of disease, lactate dehydrogenase (LDH) level, performance status, and number of extranodal sites (one or more than one), are together the most important factors in determining therapy modalities and predicting outcome of patients with aggressive NHL [3].

DLBCL typically arises in lymph nodes; however, initial extranodal sites are identified in about 30–40% of cases. Any organ system may be affected, although involvement of the gastrointestinal system is most common [1]. Primary skeletal muscle involvement by DLBCL is exceedingly rare, comprising less than 1% of cases, with the majority of cases reported arising in the lower extremity, particularly thigh and calf region [4–7]. A variety of morphologic variants have been described [8, 9]. We describe a case of primary muscle DLBCL of the upper extremity with unusual histologic features. We performed a review of lymphoma cases involving skeletal muscle diagnosed at our institution over the last 15 years, as well as thorough PubMed review of the literature. We discuss the features of lymphoma involving skeletal muscle as it pertains to clinical characteristics, histologic subtype, tumor localization, diagnostic studies, therapy, and outcome. Finally, we highlight the diagnostic difficulties that can present in these rare and often challenging cases.

2. Case Report

A 72-year-old man presented to his primary care physician (PCP) with neck pain of three-day duration, described as radiating to the upper back and shoulders. He had recalled lifting heavy wood and working a snow blower before the onset of symptoms. His past medical history is significant for hypertension, atherosclerotic disease with previous myocardial infarction (status postcoronary bypass ×3), hypercholesterolemia, hypothyroidism, and gastroesophageal reflux disease. On physical exam, neck stiffness with paraspinal
A concern for metastatic disease or lymphoma was raised left proximal humeral diaphysis with increased FDG uptake. There were also foci of mixed lytic/sclerotic lesions within the region posterior to the C1 vertebrae measuring 1.6 cm. There were multiple FDG (fludeoxyglucose) avid intramuscular foci within the left posterior upper arm corresponding to the left triceps soft tissue mass noted on MRI as well as an additional within the left posterior upper arm with mild tenderness over the left proximal humerus. There was no overlying erythema. Full range of motion was preserved. Of note, the bypass surgery graft was taken from this arm. He was referred to an orthopedic surgeon for further workup. A 5–8 cm mass was noted in the left posterior arm with mild tenderness in the right posterior neck was noted, aggravated by passive and active range of motion of the left shoulder. No neurologic signs such as tingling or numbness to the extremities, arm weakness, or gait aberrancies were noted. No cervical lymphadenopathy was present. A cervical spine X-ray revealed mild degenerative changes including endplate sclerosis, hypertrophic spurring, and disc space narrowing without erosions or unusual calcifications. An initial diagnosis of muscle spasm consistent with acute torticollis was rendered and the patient was prescribed symptomatic therapy with muscle relaxants and heat application. His pain generally resolved with only episodic recurrences. He returned to his PCP 2.5 months later for evaluation of a left upper arm painless lump that he had noticed 6–8 weeks prior to presentation. Of note, the bypass surgery graft was taken from this arm. An ultrasound revealed an approximately 7 cm heterogeneous mass comprised of intramuscular soft tissue and fluid. An MRI (magnetic resonance imaging) showed a poorly defined 12.5 × 4.5 × 2.5 cm soft tissue mass infiltrating the lateral head of the triceps muscle (Figure 1). A potential marrow replacing lesions involving the humeral head and neck and proximal humeral shaft were also noted. A staging PET (positron emission tomography) revealed multiple FDG (fludeoxyglucose) avid intramuscular foci within the left posterior upper arm corresponding to the left triceps soft tissue mass noted on MRI as well as an additional FDG avid intramuscular nodule in the right suboccipital region posterior to the Cl vertebrae measuring 1.6 cm. There were also foci of mixed lytic/sclerotic lesions within the left proximal humeral diaphysis with increased FDG uptake. A concern for metastatic disease or lymphoma was raised and a CT (computed tomography) guided biopsy and fine needle aspiration (FNA) of the muscle and the bony lesions were performed (see Section 4). A diagnosis of primary muscle DLBCL was subsequently made. The patient underwent 5 cycles of R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone) therapy. A PET CT scan after the 2nd and 5th cycle revealed CR (complete remission). The patient refused the sixth and last cycle of R-CHOP. Radiation therapy was not included in the treatment plan since a CR was observed after the second cycle of R-CHOP. Currently the patient is feeling well except for some recurring neck pain for which he is receiving symptomatic therapy (heat application and ibuprofen).

3. Materials and Methods

3.1. Histology and Immunohistochemistry. Paraffin-embedded sections of the needle core biopsies were stained with hematoxylin and eosin (H&E). Immunohistochemical stains were performed on 4 μm tissue sections using an Autostainer (Leica BOND platform, Buffalo Grove, IL). Sections were deparaffinized in xylene and graded alcohols. Detection of the antibodies was performed using a chromogenic substrate, diaminobenzene (Dako). The following antibodies were used: CD3 (RTU [ready to use], Leica), CD5 (RTU, Leica), CD10 (RTU, Leica), CD20 (L26) (RTU, Leica), CD30 (RTU, Leica), CD45 (1:200, Dako), CD79a (RTU, Leica), BCL6 (RTU, Leica), BCL2 (1:75, Dako), BCL1 (RTU, Fisher), cMYC (1:100, Epitomics), PANCK (1:75, Biogenex), AE1/AE3 (1:400, Leica), CD138 (1:200, Dako), and Ki-67 (RTU, Dako).

3.2. Cytology. Diff-Quik and Papanicolaou smears were prepared following standard protocols. Briefly, for Diff-Quik stained sections direct smear preparations were allowed to fully air-dry. After this, slide was stained using HARLECO®Hemacolor Stain Set® (Fisher). First the slide was fully immersed in Hemacolor solution I, followed by staining in Hemacolor solution II for 30 sec, counterstaining in Hemacolor solution III for 30 sec, rinsing in distilled water, air drying, dipping in xylene, and mounting. For Papanicolaou staining, the slides were dipped in ethanol, followed by hematoxylin, 2% hydrochloric acid, ethanol, OG-6 solution, EA-65 solution, ethanol, and xylene.

3.3. Search for Internal Cases and Literature Search. To analyze clinicopathologic features of muscle lymphomas, we searched the electronic database of the Hospital of University of Pennsylvania between 2000 and 2015 for all cases of lymphoma involving skeletal muscle. A systematic literature search was conducted using the PubMed database with the following keywords: muscle lymphoma, skeletal muscle lymphoma, primary muscle lymphoma, and extranodal lymphoma/NHL. All published studies (case reports and case series) in the English language literature were reviewed with respect to presenting clinicopathologic features.
Figure 2: Diff-Quik (a) and Papanicolaou (b) stained smears from the FNA of the left lateral triceps mass show predominantly larger cells with occasional clustering.

4. Results

4.1. Histology and Immunohistochemistry. The FNA specimen from the left lateral triceps revealed predominantly large malignant cells with moderately open chromatin and occasional prominent nuclei (Figures 2(a) and 2(b)). The material was insufficient for further workup. To better characterize the malignancy, a core biopsy of the lesion was performed. A portion of the specimen was submitted for flow cytometry. The H&E stained sections of the biopsy showed multiple cores of skeletal muscle diffusely involved by a dense lymphoid infiltrate forming pseudoglandular structures and sheets on low power examination (Figures 3(a) and 3(b)). On higher power examination, the cells were medium to large in size with irregular nuclear contours, vesicular chromatin, occasional prominent nuclei, and moderate amounts of cytoplasm (Figures 3(c)–3(f)). Mitoses and apoptotic debris were abundant. Sections of bone did not reveal any evidence of the tumor (not shown). By immunohistochemistry, the infiltrating cells were immunoreactive for CD45 (LCA) (Figure 4(a)), CD20 (Figure 4(b)), CD79a, BCL2 (>50%) (Figure 4(c)), CD10 (dim) (Figure 4(d)), and BCL6 (subset) and were negative for cyclin D1, CD30, c-MYC, PANCK, AE1/AE3, and CD138. The Ki-67 proliferation index was approximately 50%. The material was insufficient for additional stains. Limited flow cytometric studies from the muscle tumor revealed an expansion of apparently large, surface immunoglobulin-negative, CD10 dim and CD19 positive, and CD5 negative cells.

The combined findings were consistent with a DLBCL, best classified as germinal center subtype by Hans classifier [10]. Due to absence of tumor at other locations this lesion was best classified as primary muscle DLBCL.

4.2. Review of Internal Cases and Literature Review. This unusual case prompted a review of all cases of lymphoma involving skeletal muscle diagnosed at our institution between 2000 and 2015 (Table 1). A total of 16 cases were identified and the majority (15/16) were NHL accounting for an incidence of skeletal muscle NHL at our institution of approximately 0.2% in the last 15 years. Of the 16 cases, 8 patients were male and 8 were female and the median age was 55 (range 36–85). The most common diagnosis was DLBCL (11/16), followed by marginal zone lymphoma (MZL) (2/16), anaplastic large cell lymphoma (ALCL) (1/16), follicular lymphoma (FL) (1/16), and Hodgkin lymphoma (HL) (1/16). The site of involvement was predominantly the lower extremities and pelvic muscles (6/16), followed by neck (5/16), head (4/16), and upper extremities (1/16). Eleven patients were treated with chemotherapy or chemoimmunotherapy most commonly with CH- (cyclophosphamide, adriamycin, vincristine, and prednisone-) like regimens with the addition of rituximab. Treatment outcomes were available for nine patients and seven patients were lost to follow-up. Whereas MZL, FL, ALCL, and HL showed a secondary involvement of the muscle, DLBCL showed a primary involvement in at least 3 cases based on the available information. Only 5 of the 16 cases were noted to be associated with lymphadenopathy.

A literature search was performed to evaluate clinicopathologic features of muscle cell lymphomas and the results are summarized in Table 2. Eighty-six patients were identified that fulfilled the search criteria, of whom 52 were men and 34 were women. The median age was 57 with the range of 5–90. As with our intra-institutional cases, the most common lymphoma was DLBCL (61/86; 70.9%), followed by ALCL (6/86; 6.9%) and BL, FL, and PTCL (4/86; 4.7% each), indolent SBCL (3/86; 3.5%), NK/TCL (2/86; 2.3%), CLL (1/86; 1.2%), LBL (1/86; 1.2%), and MCL (1/86; 1.2%). The most common locations were the muscles of the lower extremities (36/86; 41.9%), followed by upper extremities (12/86; 13.9%), back (8/86; 9.3%), head/face (7/86; 8.1%), shoulder (7/86; 8.1%), pelvic (6/86; 6.9%), paraspinal (5/86; 5.8%), and rectal/anal muscles (5/86; 5.8%) and gluteal (5/86; 5.8%), chest (3/86; 3.5%), abdominal wall (2/86; 2.3%), and neck muscles (2/86; 2.3%). The majority of cases that included that information did not report associated lymphadenopathy.

While many cases from the pre-rituximab era treated with a variety of chemotherapy regimens showed poor survival, the more recent cases treated with R-CHOP showed much better outcomes.
Figure 3: Histological findings of the muscle biopsy. Low power view (H&E stain, 5x) shows dense lymphoid infiltrate forming peculiar pseudoglandular structures (a) and sheets (b). Medium (H&E stain, 20x) and high power (H&E stain, 40x) stain view of the pseudoglandular structures (c and e) and areas densely infiltrating muscle tissue (d and f).

5. Discussion

We present a case of primary skeletal muscle DLBCL with an unusual pseudoglandular morphology. The morphologic, clinical, and genetic heterogeneity of DLBCL is well known but the features seen in this case are very uncommon [1, 11, 12]. Rare cases of pseudoglandular pattern have been described in ALCL [13] but to our knowledge this is first such case in DLBCL.

Extranodal manifestations of lymphoma, especially DLBCL, are well recognized and occur in up to 40% of DLBCL patients; however, primary skeletal muscle lymphoma is very rare accounting for less than 1% of cases [4–7, 14, 15]. These cases have been associated with a worse prognosis and a more advanced age. DLBCL is the most common histologic subtype of extranodal lymphoma involving skeletal muscle (Tables 1 and 2) [16, 17]. Infiltration of the muscle by lymphoma can mimic sarcoma, metastatic carcinoma melanoma, rhabdomyoblastoma, rhabdomyosarcoma, and osteosarcoma causing diagnostic difficulties [6]. It is critical to differentiate lymphoma from sarcoma and other entities to avoid unnecessary excisions. In contrast to sarcomas, lymphomas lack extracellular stroma and intercellular junctions. The neoplastic cells of lymphoma infiltrate more readily across anatomical fascial planes, frequently involving more than one muscle compartment [6, 16]. In addition lymphoma can exhibit confluent lymphadenopathy not seen in sarcoma [6]. The muscle
Figure 4: Immunohistochemical findings of the muscle biopsy. (a) Low power view (5x) reveals that CD45 stain highlights the pseudoglandular structures that are also immunoreactive for (b) CD20 (10x), (c) BCL2 (10x), and (d) CD10 (10x).

Table 1: Clinical characteristics, diagnosis, treatment, and follow-up in 16 patients with muscle lymphoma diagnosed at our institution between 2000 and 2015.

| Location/muscle         | Age | Gender | Diagnosis    | Treatment         | Follow-up                      |
|-------------------------|-----|--------|--------------|--------------------|--------------------------------|
| Piriformis muscle       | 50  | M      | DLBCL        | R-CHOP + RT       | Alive in CR at 6 years        |
| Thigh muscle            | 55  | M      | ALCL, ALK−   | CHOP/ONTAK         | Lost to follow-up             |
| Iliacus muscle          | 52  | M      | DLBCL        | R-CHOP             | Died at 3 months              |
| Psoas muscle            | 60  | M      | DLBCL        | R-CE               | Alive with PD at 28 months    |
| Triceps muscle          | 79  | M      | DLBCL        | R-CHOP             | Alive in CR at 6 months       |
| Psoas muscle            | 70  | F      | DLBCL        | NR                 | NR                             |
| Sternotothyroid muscle  | 57  | F      | DLBCL        | R-CHOP + RT       | Alive in CR at 14 years       |
| Temporalis muscle       | 45  | M      | MZL          | FCR                | Alive in CR at 10 years       |
| Cervical muscle         | 78  | M      | DLBCL        | R-CHOP             | Alive in CR at 10 years       |
| Iliacus muscle          | 85  | F      | DLBCL        | R-CHOP + RT       | Died at 24 months             |
| Buccal muscle           | 36  | M      | DLBCL        | NR                 | Lost to follow-up             |
| Right buccal            | 55  | F      | DLBCL        | NR                 | Lost to follow-up             |
| Buccal muscle           | 50  | F      | FL, low-grade| R-CHOP             | Lost to follow-up             |
| Strap muscle            | 42  | F      | HL           | ABVD               | Alive in CR at 10 years       |
| Neck muscles            | 54  | F      | DLBCL        | NR                 | Lost to follow-up             |
| Neck muscles            | 79  | F      | MZL          | NR                 | Lost to follow-up             |

ABVD = adriamycin, bleomycin, vinblastine, and dacarbazine; ALCL = anaplastic large T-cell lymphoma; ALK = anaplastic lymphoma kinase; CHOP = cyclophosphamide, adriamycin, vincristine, and prednisone; CR = complete response; DLBCL = diffuse large B-cell lymphoma; F = female; FCR = fludarabine, cyclophosphamide, and rituximab; FL = follicular lymphoma; HL = Hodgkin lymphoma; M = male; MZL = marginal zone lymphoma; NR = not reported; ONTAK = denileukin diftitox; PD = progressive disease; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CE: rituxan-cytoxan-etoposide; RT = radiation therapy.
Table 2: Clinicopathologic characteristics of 86 patients from the literature with reported muscle lymphoma.

| Patients, n | 86 |
|-------------|----|
| Sex, male/female | 52/34 |
| Age median (range) | 57 (5–90) |
| <18 years | 5 |

| Histology | Patients, n (%) |
|-----------|----------------|
| DLBCL | 61 (70.9) |
| ALCL* | 6 (6.9) |
| BL | 4 (4.7) |
| FL | 4 (4.7) |
| PTCL | 4 (4.7) |
| Indolent SBCL, type not specified | 3 (3.5) |
| NK/TCL | 2 (2.3) |
| CLL | 1 (1.2) |
| LBL | 1 (1.2) |
| MCL | 1 (1.2) |

| Location | Patients, n (%) |
|----------|----------------|
| Lower extremities | 36 (41.9) |
| Upper extremities | 12 (13.9) |
| Back | 8 (9.3) |
| Head/face | 7 (8.1) |
| Shoulder | 7 (8.1) |
| Pelvic | 6 (6.9) |
| Paraspinal | 5 (5.8) |
| Rectal/anal | 5 (5.8) |
| Gluteal | 5 (5.8) |
| Chest | 3 (3.5) |
| Abdominal wall | 2 (2.3) |
| Neck | 2 (2.3) |

*3 cases with ALK+/2 cases ALK− case ALK not reported.

Involvement by lymphoma can be either primary or secondary (generally secondary to bone involvement). Frequently, cases of lymphoma involving skeletal muscle present with muscle pain, swelling, and a rapidly enlarging mass [5, 6]. The most commonly affected muscles are those of the extremities; however, other more unusual locations have been reported (Table 2) [5, 18]. Rare cases of DLBCL involving facial muscles and muscles of mastication can present with facial hemiplegia, paresthesia, and/or swelling [14, 19–21]. Muscle DLBCL can also be the cause of neurological complications due to nerve root entrapment and should be considered as an important cause of cranial peripheral nerve palsy or a piriformis syndrome [19, 22, 23]. Rarely, muscle lymphoma can present as an acute compartment syndrome [24]. It can also cause diffuse skin and soft tissue changes that may be suggestive of cellulitis [25] and has been reported to be a rare cause for a perianal abscess [26]. A potential contributing factor that may lead to the development of lymphoma in the muscle is a prior injury at that site. In fact, cases of primary muscle lymphoma following leg injury and needle injections and in rectum of homosexual men have been described [27–30]. Although NHL risk is increased in HIV-positive patients, primary muscle lymphomas in this patient population are rare with only few reported cases [14, 29–32].

A systematic study of 82 autopsy cases published in 1996 that investigated neoplastic infiltration in skeletal muscle in patients with lymphoma concluded that in contrary to scant literature reports on the subject skeletal muscle involvement in lymphoma is not such a rare phenomenon [33]. Muscle involvement was seen in 16% of lymphosarcoma (now designated NHL). 18% of reticulum cell sarcoma (now designated follicular dendritic cell tumor), and 6.8% of Hodgkin disease. The majority of the muscle groups affected were intercostal, psoas, diaphragm, and sternothyroid muscles [33]. Another postmortem series of 194 patients who died of malignancy found skeletal muscle involvement in 20.6% of their lymphoma cases [34]. This raises a concern that muscle lymphoma may be more prevalent than currently appreciated.

Imaging studies are critical in the diagnostic workup of lymphoma in the muscle. MRI is the preferred technology to assess the extent of the mass within bone and surrounding tissues as it can offer higher soft tissue contrast and multiplanar imaging view [35–37]. Findings that are suggestive of primary muscular lymphoma include involvement of multiple muscular compartments and possible involvement of adjacent subcutaneous tissue and skin thickening. PET scan is mandatory for staging and evaluation of response and CT and scintigraphy play a complementary role and should only be used as initial examination and for staging purposes [28, 35, 36]. CT typically reveals nonspecific findings of a hypodense or isodense mass in the muscles that are not sufficient for accurate evaluation [38, 39]. Plain radiographs may be unremarkable or just show soft tissue swelling [36]. Sonography may show an ill-defined hypoechoic lesion, thickened fibroadipose septa, and swelling of soft tissue [40]. Although imaging studies are an important step in the workup of patients with muscle lymphoma, histological examination is necessary to confirm the diagnosis. Diagnosing of skeletal DLBCL on a small needle core biopsy especially in cases with unusual morphology may be very challenging and having a larger core biopsy with more material may be paramount for the diagnosis. Following the diagnosis of lymphoma, staging should be performed to select appropriate treatment.

The standard treatment for DLBCL is now combination chemotherapy and immunotherapy, known as R-CHOP (rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone) with or without radiation therapy but the presentation in unusual sites may require specific treatment approaches. Patients with extranodal NHL present more frequently with early stage disease compared with those with nodal NHL; overall survival in both groups largely depends on IPI (international prognostic index) and not on the site of origin of the malignancy [41]. Hence, although cases of primary skeletal DLBCL may be undertreated overall, if diagnosed early and correctly patients have a likelihood to
achieve complete response upon treatment with R-CHOP [5, 42, 43].

In conclusion, primary skeletal muscle lymphoma is a rare entity and the majority of the cases belong to the group of DLBCL. MRI is the preferred technology in the diagnostic workup of potential skeletal muscle lymphoma. Due to a broad differential diagnosis of muscle lesions, a biopsy and histological examination are paramount for the diagnosis. The first-line treatment consists of R-CHOP; however modifications should be considered in more challenging cases.

Competing Interests

The authors declared no potential competing interests with respect to the research, authorship, and/or publication of this paper.

References

[1] S. H. Swerdlow, E. Campo, N. L. Harris et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, France, 4th edition, 2008.

[2] J. W. Friedberg and R. I. Fisher, “Diffuse large B-cell lymphoma,” Hematology/Oncology Clinics of North America, vol. 22, no. 5, pp. 941–952, 2008.

[3] J. O. Armitage, “My treatment approach to patients with diffuse large B-cell lymphoma,” Mayo Clinic Proceedings, vol. 87, no. 2, pp. 161–171, 2012.

[4] W. D. Travis, P. M. Banks, and H. M. Reiman, “Primary extranodal soft tissue lymphoma of the extremities,” The American Journal of Surgical Pathology, vol. 11, no. 5, pp. 359–366, 1987.

[5] L. Bourdeau, R. Menon, and G. Somlo, “Diffuse large B-cell lymphoma with calf muscle localization,” Case Reports in Hematology, vol. 2011, Article ID 292494, 3 pages, 2011.

[6] A. Alamdari, N. Naderi, S. Peiman, and F. Shahi, “Non-Hodgkin lymphoma with primary involvement of skeletal muscle,” International Journal of Hematology-Oncology and Stem Cell Research, vol. 8, no. 3, pp. 55–57, 2014.

[7] A. G. Glass, L. H. Karnell, and H. R. Menck, “The national cancer data base report on non-Hodgkin’s lymphoma,” Cancer, vol. 80, no. 12, pp. 2311–2320, 1997.

[8] J. van Baarlen, H.-J. Schuurman, and J. A. M. van Unnik, “Multilobated cells,” Cancer, vol. 61, no. 7, pp. 1371–1376, 1988.

[9] C. K. Pettit, L. R. Zukerberg, M. H. Gray et al., “Primary lymphoma of bone. A B-cell neoplasm with a high frequency of multilobated cells,” The American Journal of Surgical Pathology, vol. 14, no. 4, pp. 329–334, 1990.

[10] C. P. Hans, D. D. Weisenburger, T. C. Greiner et al., “Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray,” Blood, vol. 103, no. 1, pp. 275–282, 2004.

[11] S. Gurbuxani, J. Anastasi, and E. Hyjek, “Diffuse large B-cell lymphoma—more than a diffuse collection of large B cells: an entity in search of a meaningful classification,” Archives of Pathology & Laboratory Medicine, vol. 133, no. 7, pp. 1121–1134, 2009.

[12] M. P. Menon, S. Pittaluga, and E. S. Jaffe, “The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization Classification,” Cancer Journal, vol. 18, no. 5, pp. 411–420, 2012.

[13] N. Stiouts and M. E. Kadin, “Perivascular Ki-1 + lesions,” International Journal of Hematology, vol. 55, no. 3, pp. 275–279, 1992.

[14] J. Chong, P. M. Som, A. R. Silvers, and J. F. Dalton, “Extranodal non-Hodgkin lymphoma involving the muscles of mastication,” American Journal of Neuroradiology, vol. 19, no. 10, pp. 1849–1851, 1998.

[15] M. J. Kransdorf, “Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location,” American Journal of Roentgenology, vol. 164, no. 1, pp. 129–134, 1995.

[16] J. K. O’Neill, V. Devaraj, D. A. T. Silver, P. Sarsfield, and C. A. Stone, “Extranodal lymphomas presenting as soft tissue sarcomas to a sarcoma service over a two-year period,” Journal of Plastic, Reconstructive and Aesthetic Surgery, vol. 60, no. 6, pp. 646–654, 2007.

[17] E. Derenzini, B. Casadei, C. Pellegrini, L. Argnani, S. Pilleri, and P. L. Zinzani, “Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series,” Clinical Lymphoma, Myeloma and Leukemia, vol. 13, no. 3, pp. 258–265, 2013.

[18] L. Zhang, Q. Lin, L. Zhang, L. Dong, and Y. Li, “Primary skeletal muscle diffuse large B cell lymphoma: a case report and review of the literature,” Oncology Letters, vol. 10, no. 4, pp. 2156–2160, 2015.

[19] Y. Amo, R. Tanei, K. Yonemoto, K. Katsuoka, and M. Mori, “Diffuse large B-cell lymphoma associated with skin, muscle and cranial nerve involvement,” European Journal of Dermatology, vol. 10, no. 4, pp. 306–308, 2000.

[20] C. CeySENS, M. Horvath, J. L. Termote, and S. F. Lemahieu, “Extranodal non-Hodgkin lymphoma of the head and neck presenting as a mandibular swelling: report of two cases,” Journal Belge de Radiologie, vol. 75, no. 1, pp. 37–39, 1992.

[21] P. A. K. Set, J. M. Somers, P. D. Britton, and C. E. L. Freer, “Pictorial review: benign and malignant enlargement of the pterygo-masseteric muscle complex,” Clinical Radiology, vol. 48, no. 1, pp. 57–60, 1993.

[22] G. M. Jeffery, P. F. Golding, and G. M. Mead, “Non-Hodgkin’s lymphoma arising in skeletal muscle,” Annals of Oncology, vol. 2, no. 7, pp. 501–504, 1991.

[23] B. S. Ye, J. N. Sunwoo, B. C. Suh, J.-P. Park, D.-S. Shim, and S. M. Kim, “Diffuse large B-cell lymphoma presenting as piriformis syndrome,” Muscle and Nerve, vol. 41, no. 3, pp. 419–422, 2010.

[24] S. R. Southworth, N. P. O’Malley, N. A. Ebraheim, L. Zeff, and V. Cummings, “Compartment syndrome as a presentation of non-hodgkin’s lymphoma,” Journal of Orthopaedic Trauma, vol. 4, no. 4, pp. 470–473, 1990.

[25] L. M. Baddour, K. H. Haden, and J. W. Allen, “Primary skeletal muscle lymphoma presenting as refractory cellulitis,” Cutis, vol. 68, no. 3, pp. 223–226, 2001.

[26] H. Jayasekera, K. Gorissen, L. Francis, and C. Chow, “Diffuse large B cell lymphoma presenting as a peri-anal abscess,” Journal of Surgical Case Reports, vol. 2014, no. 6, 2014.

[27] O. Shipilberg, M. Azaria, S. Apter, B. Friedman, S. Engelberg, and M. Ehrenfeld, “Primary striated muscle lymphoma presenting in an amputation stump,” Israel Journal of Medical Sciences, vol. 25, no. 2, pp. 116–117, 1989.

[28] R. Sonnino and A. A. Kambouris, “Malignant lymphoma presenting in gluteal muscles: case report and brief review of the literature,” Henry Ford Hospital Medical Journal, vol. 36, no. 1, pp. 61–63, 1988.
[29] X. Chevalier, Z. Amoura, J.-P. Viard, B. Souissi, A. Sobel, and R. Gherardi, "Skeletal muscle lymphoma in patients with the acquired immunodeficiency syndrome: a diagnostic challenge," *Arthritis and Rheumatism*, vol. 36, no. 3, pp. 426–427, 1993.

[30] R. L. Burkes, P. R. Meyer, P. S. Gill, J. W. Parker, S. Rasheed, and A. M. Levine, "Rectal lymphoma in homosexual men," *Archives of Internal Medicine*, vol. 146, no. 5, pp. 913–915, 1986.

[31] D. Marotta, A. Sgambato, S. Cerciello et al., "Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature," *World Journal of Surgical Oncology*, vol. 6, article III, 2008.

[32] C. Katusiime and A. Kambugu, "A rare entity of primary extranodal diffuse large B cell lymphoma of the lower limb calf in an HIV-infected young adult on highly active antiretroviral therapy," *BMJ Case Reports*, 2012.

[33] L. F. Buenger and P. N. Monteleone, "Leukemic-lymphomatous infiltration of skeletal muscle. Systematic study of 82 autopsy cases," *Cancer*, vol. 19, no. 10, pp. 1416–1422, 1966.

[34] O. Acinas García, F. A. Fernández, E. G. Satué, L. Buerta, and J. F. Val-Bernal, "Metastasis of malignant neoplasms to skeletal muscle," *Revista Espanola de Oncologia*, vol. 31, no. 1, pp. 57–67, 1984.

[35] S. Suresh, A. Saifuddin, and P. O’Donnell, "Lymphoma presenting as a musculoskeletal soft tissue mass: MRI findings in 24 cases," *European Radiology*, vol. 18, no. 11, pp. 2628–2634, 2008.

[36] V. S. Lee, S. Martinez, and R. E. Coleman, "Primary muscle lymphoma: clinical and imaging findings," *Radiology*, vol. 203, no. 1, pp. 237–244, 1997.

[37] C. W. Chun, W.-H. Jee, H. J. Park et al., "MRI features of skeletal muscle lymphoma," *American Journal of Roentgenology*, vol. 195, no. 6, pp. 1355–1360, 2010.

[38] M. E. Caporale, G. F. Gambino, F. S. Larosa, A. Del Buono, and F. Di Segni, "Non-Hodgkin’s lymphoma: unexpected cause of shoulder pain. A systematic review of the literature," *Muscles, Ligaments and Tendons Journal*, vol. 3, no. 3, pp. 236–239, 2013.

[39] S. Eustace, C. S. Winalski, A. McGowen, H. Lan, and D. Dorfman, "Skeletal muscle lymphoma: observations at MR imaging," *Skeletal Radiology*, vol. 25, no. 5, pp. 425–430, 1996.

[40] R. Arkun, A. Memis, E. Sevinc, and E. E. Ustun, "Sonographic demonstration of skeletal muscle invasion by lymphoma," *American Journal of Roentgenology*, vol. 160, no. 5, p. 1151, 1993.

[41] A. Lal, Y. Bhurgri, I. Vaziri et al., "Extranodal non-Hodgkin’s lymphomas—a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin’s lymphomas," *Asian Pacific Journal of Cancer Prevention*, vol. 9, no. 3, pp. 453–458, 2008.

[42] M. J. J. Kuper-Hommel, S. A. M. Van De Schans, G. Vreugdenhil, J. H. Van Krieken, and J.-W. W. Coebergh, "Undertreatment of patients with localized extranodal compared with nodal diffuse large B-cell lymphoma," *Leukemia and Lymphoma*, vol. 54, no. 8, pp. 1698–1705, 2013.

[43] M. Katsura, H. Nishina, Y. Shigemori, and T. Nakanishi, "Extranodal lymphoma originating in the gluteal muscle with adjacent bone involvement and mimicking a soft tissue sarcoma," *International Journal of Surgery Case Reports*, vol. 7, pp. 161–164, 2015.